NR3C2 and cardiomyopathy: DMD-associated cardiomyopathy may be delayed and improved with steroids and cardioprotective therapies (e.g., ACE inhibitors, β-blockers, and mineralocorticoid receptor antagonists) (4, 8, 24, 25).